Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Completed 10Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Glioblastoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × dactolisib × Clear all
NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

University of Cincinnati

Phase 1 Terminated
19 enrolled
CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡